Holen Sie sich die Stockscreener-App
3.60
6.98%
-0.27
Handel nachbörslich:
3.67
0.07
+1.94%
Nervgen Pharma Corp Aktie (NGEN) Neueste Nachrichten
NervGen Pharma to delist shares from TSX - TipRanks
NervGen Pharma (NGEN) to Voluntarily Delist from TSX Venture Exc - GuruFocus
NervGen Pharma to Delist from TSX Venture Exchange, Keep Nasdaq Listing as NVG-291 Advances - TipRanks
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange - Yahoo Finance
NervGen appoints regulatory and patient advocacy executives By Investing.com - Investing.com Nigeria
NervGen Pharma price target raised to C$6.75 from C$5 at Stifel - TipRanks
Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP - TipRanks
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP of Patient Advocacy - geneonline.com
NervGen appoints regulatory and patient advocacy executives - Investing.com
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs - The Manila Times
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program - TipRanks
Spinal Cord Injury Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development - StreetInsider
NGENFNervgen Pharma Corp Latest Stock News & Market Updates - Stock Titan
NervGen Pharma to Participate at Upcoming Investor Conferences - The Manila Times
How NervGen Pharma Corp. (9UA) stock reacts to weak economy2025 Dividend Review & Low Risk High Win Rate Picks - mfd.ru
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - The Manila Times
NervGen Pharma appoints Dr. Adam Rogers as CEO and president By Investing.com - Investing.com Nigeria
Why NervGen Pharma Corp. (9UA) stock stays on buy listsInsider Selling & High Conviction Investment Ideas - mfd.ru
Why NervGen Pharma Corp. (9UA) stock could be next leader2025 Price Momentum & Growth Focused Stock Pick Reports - mfd.ru
NervGen Pharma to Present at Unite2Fight Paralysis 20th Annual Science and Advocacy Symposium - marketscreener.com
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium - The Manila Times
NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development - MSN
NervGen Pharma appoints new president & CEO - MSN
NervGen Pharma appoints Dr. Adam Rogers as CEO and president - Investing.com
NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal - TipRanks
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury - marketscreener.com
NervGen Pharma names Adam Rogers as CEO - The Pharma Letter
NervGen Pharma Confirms Adam Rogers as CEO to Steer Next Growth Phase - TipRanks
NervGen appoints Rogers as CEO to lead neuroreparative drug development By Investing.com - Investing.com Australia
NervGen Pharma Names Adam Rogers Permanent CEO to Drive Next Growth Phase - TipRanks
NervGen Pharma Appoints New CEO Adam Rogers - Intellectia AI
Adam Rogers Appointed CEO of NervGen Pharma to Advance Spinal Cord Injury Treatment Efforts - geneonline.com
NGEN: NervGen Pharma Appoints New CEO to Advance NVG-291 - GuruFocus
NervGen Pharma Names Adam Rogers as CEO - marketscreener.com
NervGen appoints Rogers as CEO to lead neuroreparative drug development - Investing.com
NervGen Pharma Corp appoints Adam Rogers as chief executive officer - marketscreener.com
NervGen Pharma Corp. Appoints Adam Rogers as Chief Executive Officer, Effective February 9, 2026 - marketscreener.com
New drug may help spinal cord injury patients regain function and hope - WGN-TV
When Will NervGen Pharma Corp. (CVE:NGEN) Breakeven? - Yahoo Finance
Johnson & Johnson receives CHMP positive opinion for AKEEGA - marketscreener.com
Analysts Expect Breakeven For NervGen Pharma Corp. (CVE:NGEN) Before Long - simplywall.st
Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma - Barchart.com
NervGen Pharma Rings the Closing Bell - Nasdaq
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):